News

ERC puts €680m into research
Enlarge image

FundingSwitzerlandEU

ERC puts €680m into research

24.01.2013 - The European Research Council (ERC) has awarded €680m to 302 top basic researchers in 24 EU countries.

The awards are part of the latest series of the ERC’s Advanced Grants, which give up to €2.5m per researcher to pursue ground-breaking ideas at the frontiers of knowledge. Life Science researchers were very successful in this call, bagging 37% of the total funding cake. However, at only 13%, the ERC grant’s success rate is very low compared to other funding programmes. The European Commission has proposed to expand the ERC's budget significantly in its 2014-2020 innovation programme Horizon 2020. Negotiations with the member states about the long-term EU budget including Horizon2020, however, were cancelled at the end of last year. This is why the ERC has now begun to extend its lobbying activities.

ERC representative Helga Nowotny, thus, for the first time attended the World Economic Forum (WEF) in Davos to embrace industry and policymakers. ”The health and wealth of future societies greatly depend on maintaining the long-term perspectives that science offers,“ said ERC chief Nowotny.."Investment in research, education and innovation is even more important in times of budgetary austerity, in Europe and elsewhere. Leaders from all fields, including business, understand this dynamic, but need to find novel ways of joining forces. We truly believe that science, as well as technology and innovation, will emerge as a common theme of interest to shape the agenda of the future decades”.

The idea to catalyse actions for putting science, technology and innovation on the global agenda has already started and is likely to be prominent in this year's forum. There is growing awareness amongst policy-makers worldwide and public research organisations, of the fact that globalisation of science offers unprecedented opportunities for cooperation. In Davos, one of the sessions will be devoted to how decision-makers, business, civil society and academia can join forces to build a new vision based on frontier research, scientific discoveries and innovation.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/erc-funds-researchers-with-eur680m.html

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

ResearchUKSwitzerland

03.08.2014 In its efforts to become the leading country in genetic research, the UK has attracted investments worth more than £300m (€376m) to map 100,000 human genomes by 2017.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN7.85 EUR5.65%
  • CYTOS0.26 CHF4.00%
  • PAION2.48 EUR2.06%

FLOP

  • 4SC1.25 EUR-2.34%
  • FORMYCON6.75 EUR-1.75%
  • VITA 343.75 EUR-1.57%

TOP

  • SANTHERA83.50 CHF21.8%
  • MAGFORCE6.90 EUR10.8%
  • BB BIOTECH140.45 EUR5.1%

FLOP

  • WILEX2.36 EUR-25.1%
  • MOLOGEN7.85 EUR-19.5%
  • VITA 343.75 EUR-17.6%

TOP

  • SANTHERA83.50 CHF3695.5%
  • CO.DON2.61 EUR226.2%
  • PAION2.48 EUR188.4%

FLOP

  • CYTOS0.26 CHF-93.5%
  • MEDIGENE4.48 EUR-68.1%
  • MERCK KGAA66.20 EUR-43.4%

No liability assumed, Date: 26.08.2014